Neuron-specifi c enolase as a biomarker: Biochemical and clinical aspects

Advances in Experimental Medicine and Biology

Volumn 867, Issue , 2015, Pages 125-143

  Isgrò, Maria Antonietta ^a   Bottoni, Patrizia ^a   Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

ENO1; ENO2; ENO3; Neuron specifi c enolase (NSE); NSE as biomarker; NSE assays in body fl uids; NSE biochemical properties; NSE clinical indications; NSE in brain damage; NSE in gastroenteropancreatic neuroendocrine tumours; NSE in lung cancer; NSE in melanoma; NSE in neuroblastoma; NSE in neuroendocrine tumours; NSE in seminoma; NSE mapping and gene function; Tissue NSE expression

Indexed keywords

NEURON SPECIFIC ENOLASE; ENOLASE; TUMOR MARKER;

AMINO ACID SEQUENCE; BIOCHEMICAL ANALYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER PROGNOSIS; CANCER STAGING; CLINICAL EVALUATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENO1 GENE; ENO2 GENE; ENO3 GENE; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME STRUCTURE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE; GENE FUNCTION; GENE MAPPING; HEART ARREST; HISTORY OF MEDICINE; HUMAN; MELANOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESUSCITATION; SEMINOMA; SMALL CELL LUNG CANCER; TISSUE DISTRIBUTION; TRAUMATIC BRAIN INJURY; TUMOR VOLUME; BODY FLUID; CHEMISTRY; GENETICS; NEOPLASMS;

AMINO ACID SEQUENCE; BIOMARKERS, TUMOR; BODY FLUIDS; HUMANS; NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE;

EID: 84946781904     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-94-017-7215-0_9     Document Type: Chapter

References (127)

1. Moore BW, McGregor T (1965) Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem 240:1647–1653
2. Pickel VM, Reis DJ, Marangos PJ et al (1976) Immunocytochemical localization of nervous system specifi c protein (NSP-R) in rat brain. Brain Res 105:184–187
3. Bock E, Dissing J (1975) Demonstration of enolase activity connected to the brainspecifi c protein 14-3-2 Scand J Immunol 4(suppl 2):31–36
4. Marangos PJ, Zomzely-Neurath C, York C (1976) Determination and characterization of neuron specifi c protein (NSP) associated enolase activity. Biochem Biophys Res Commun 68:1309–1316
5. Wold F, Ballou CE (1957) Studies on the enzyme enolase. II. Kinetic studies. J Biol Chem 227:313–328
6. Brewer JM (1985) Specifi city and mechanism of action of metal ions in yeast enolase. FEBS Lett 182:8–14
7. Faller LD, Baroudy BM, Johnson AM et al (1977) Magnesium ion requirements for yeast enolase activity. Biochemistry 16:3864–3869
8. Brewer JM, Weber G (1966) The effect of magnesium on some physical properties of yeast enolase. J Biol Chem 241:2550–2557
9. Faller LD, Johnson AM (1974) Calorimetric studies of the role of magnesium ions in yeast enolase catalysis. Proc Natl Acad Sci U S A 71:1083–1087
10. Hanlon DP, Westhead EW (1969) Kinetic studies on the activation of yeast enolase by divalent cations. Biochemistry 8:4255–4260
11. Brewer JM (1971) The increase of yeast enolase fl uorescence produced by substrates and competitive inhibitors in the presence of excess Mg 2+. Biochim Biophys Acta 250:251–257
12. Poyner RR, Cleland WW, Reed GH (2001) Role of metal ions in catalysis by enolase: an ordered kinetic mechanism for a single substrate enzyme. Biochemistry 40:8009–8017
13. Marangos PJ, Zis AP, Clark RL et al (1978) Neuronal, non-neuronal and hybrid forms of enolase in brain: structural, immunological and functional comparisons. Brain Res 150:117–133
14. Schmechel DE, Brightman MW, Marangos PJ et al (1978) Granule cell neurons in developing rat and monkey cerebellum change from glial to neuronal enolase. J Anat 4:126
15. Schmechel D, Marangos PJ, Zis AP et al (1978) Brain enolases as specifi c markers of neuronal and glial cells. Science 199:313–315
16. Marangos PJ, Schmechel DE (1987) Neuron specifi c enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 10:269–295
17. Chai G, Brewer JM, Lovelace LL et al (2004) Expression, purifi cation and the 1.8 angstroms resolution crystal structure of human neuron specifi c enolase. J Mol Biol 341:1015–1021
18. McAleese SM, Dunbar B, Fothergill JE et al (1988) Complete amino acid sequence of the neuronespecifi c gamma isozyme of enolase (NSE) from human brain and comparison with the non-neuronal alpha form (NNE). Eur J Biochem 178:413–417
19. Giallongo A, Feo S, Moore R et al (1986) Molecular cloning and nucleotide sequence of a full-length cDNA for human alpha enolase. Proc Natl Acad Sci U S A 83:6741–6745
20. Oliva D, Calì L, Feo S et al (1991) Complete structure of the human gene encoding neuron-specifi c enolase. Genomics 10:157–165
21. Sakimura K, Kushiya E, Takahashi Y et al (1987) The structure and expression of neuron-specifi c enolase gene. Gene 60:103–113
22. Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321:209–213
23. Haimoto H, Takahashi Y, Koshikawa T et al (1985) Immunohistochemical localization of gammaenolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 52:257–263
24. Van Obberghen E, Kamholz J, Bishop JG 3rd et al (1988) Human gamma enolase: isolation of a cDNA clone and expression in normal and tumor tissues of human origin. J Neurosci Res 19:450–456
25. Meera Khan P, Doppert BA, Hagemeijer A et al (1974) The human loci for phosphopyruvate hydratase and guanylate kinase are syntenic with the PGDPGM1 linkage group in man-Chinese hamster somatic cell hybrids. Cytogenet Cell Genet 13:130–131
26. Cook PJ, Hamerton JL (1979) Report of the committee on the genetic constitution of chromosome 1 Cytogenet Cell Genet 25:9–20
27. Grzeschik KH (1976) Assignment of human genes: beta-glucuronidase to chromosome 7, adenylate kinase-1 to 9, a second enzyme with enolase activity to 12, and mitochondrial IDH to 15. Birth Defects Orig Artic Ser 12:142–148
28. Law ML, Kao FT (1982) Regional mapping of the gene coding for enolase-2 on human chromosome 12. J Cell Sci 53:245–254
29. Craig SP, Day IN, Thompson RJ et al (1990) Localisation of neurone-specifi c enolase (ENO2) to 12p13. Cytogenet Cell Genet 54:71–73
30. Feo S, Oliva D, Barbieri G et al (1990) The gene for the muscle-specifi c enolase is on the short arm of human chromosome 17. Genomics 6:192–194
31. Muller FL, Colla S, Aquilanti E et al (2012) Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488:337–342
32. Rider CC, Taylor CB (1974) Enolase isoenzymes in rat tissues. Electrophoretic, chromatographic, immunological and kinetic properties. Biochim Biophys Acta 365:285–300
33. Schmechel DE, Brightman MW, Marangos PJ (1980) Neurons switch from non-neuronal enolase to neuron-specifi c enolase during differentiation. Brain Res 190:195–214
34. Tanaka M, Sugisaki K, Nakashima K (1985) Switching in levels of translatable mRNAs for enolase isozymes during development of chicken skeletal muscle. Biochem Biophys Res Commun 133:868–872
35. Marangos PJ, Schmechel DE, Parma AM et al (1980) Developmental profi le of neuron-specifi c (NSE) and non-neuronal (NNE) enolase. Brain Res 190:185–193
36. Chen SH, Omenn GS (1984) Human neuron-specifi c enolase: genetic and developmental studies. J Neurogenet 1:159–164
37. Nobels FR, Kwekkeboom DJ, Coopmans W et al (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuronspecifi c enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82:2622–2628
38. Eriksson B, Oberg K, Stridsberg M (2000) Tumor markers in neuroendocrine tumors. Digestion 62(Suppl 1):33–38
39. Baudin E, Gigliotti A, Ducreux M et al (1998) Neuron-specifi c enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78:1102–1107
40. Bajetta E, Ferrari L, Martinetti A et al (1999) Chromogranin A, neuron specifi c enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86:858–865
41. Carney DN, Teeling M (1988) Neuron-specifi c enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol 24:825–828
42. Marangos PJ, Zomzely-Neurath C, York C (1975) Immunological studies of a nerve specifi c protein. Arch Biochem Biophys 170:289–293
43. Marangos PJ, Schmechel D, Parma AM et al (1979) Measurement of neuron-specifi c (NSE) and nonneuronal (NNE) isoenzymes of enolase in rat, monkey and human nervous tissue. J Neurochem 33:319–329
44. Parma AM, Marangos PJ, Goodwin FK (1981) A more sensitive radioimmunoassay for neuronspecifi c enolase suitable for cerebrospinal fl uid determinations. J Neurochem 36:1093–1096
45. Wevers RA, Jacobs AA, Hommes OR (1983) A bioluminescent assay for enolase (EC 4.2.1.11) activity in human serum and cerebrospinal fl uid. Clin Chim Acta 135:159–168
46. Gerbitz KD, Summer J, Thallemer J (1984) Brainspecifi c proteins: solid-phase immunobioluminescence assay for neuron-specifi c enolase in human plasma. Clin Chem 30:382–386
47. Kimura S, Uchikawa H, Yamamoto R et al (1984) Practicable enzyme immunoassay for neuron- specifi c enolase in human serum. J Appl Biochem 6:319–324
48. Kimura S, Uchikawa H, Yamamoto R et al (1986) Two-site column enzyme immunoassay for neuronspecifi c enolase (NSE) in human serum using monoclonal antibodies. J Immunol Methods 94:51–55
49. Viallard JL, Murthy MR, Bétail G et al (1986) Determination of serum neuron-specifi c enolase by differential immunocapture. Clin Chim Acta 161:1–10
50. Viallard JL, Ven Murthy MR, Dastugue B (1986) Rapid electrophoretic determination of neuronspecifi c enolase isoenzymes in serum. Clin Chem 32:593–597
51. Anastasiades KD, Mullins RE, Conn RB (1987) Neuron-specifi c enolase. Assessment by ELISA in patients with small cell carcinoma of the lung. Am J Clin Pathol 87:245–249
52. Paus E, Nustad K (1989) Immunoradiometric assay for alpha gamma- and gamma gamma-enolase (neuron- specifi c enolase), with use of monoclonal antibodies and magnetizable polymer particles. Clin Chem 35:2034–2038
53. Body JJ, Paesmans M, Sculier JP et al (1992) Monoclonal immunoradiometric assay and polyclonal radioimmunoassay compared for measuring neuron-specifi c enolase in patients with lung cancer. Clin Chem 38:748–751
54. Schmitt UM, Stieber P, Hasholzner U et al (1996) Methodological and clinical evaluation of two automated enzymatic immunoassays as compared with a radioimmunoassay for neuron-specifi c enolase. Eur J Clin Chem Clin Biochem 34:679–682
55. Ebert W, Muley T (1998) Analytical performance of the new single step COBAS Core NSE EIA II and its diagnostic utility in comparison with the established COBAS Core NSE EIA. Clin Lab 44:871–879
56. Muley T, Ebert W, Stieber P et al (2003) Technical performance and diagnostic utility of the new Elecsys neuron-specifi c enolase enzyme immunoassay. Clin Chem Lab Med 41:95–103
57. Fu X, Meng M, Zhang Y et al (2012) Chemiluminescence enzyme immunoassay using magnetic nanoparticles for detection of neuron specifi c enolase in human serum. Anal Chim Acta 722:114–118
58. Torsetnes SB, Løvbak SG, Claus C et al (2013) Immunocapture and LC-MS/MS for selective quantifi cation and differentiation of the isozymes of the biomarker neuron-specifi c enolase in serum. J Chromatogr B Analyt Technol Biomed Life Sci 929:125–132
59. Li GZ, Tian F (2013) Guanine-decorated graphene nanostructures for sensitive monitoring of neuronspecifi c enolase based on an enzyme-free electrocatalytic reaction. Anal Sci 29:1195–1201
60. Mercer DW, Virji MA, Barry GE, Piper ML (1990) New solid-phase enzyme immunoassay of neuronspecifi c enolase in serum: effect of storage temperature, lipemia, icterus, and hemolysis. Clin Chem 36:1519
61. Gerbitz KD, Summer J, Schumacher I et al (1986) Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem 24:1009–1016
62. Ramont L, Thoannes H, Volondat A et al (2005) Effects of hemolysis and storage condition on neuron- specifi c enolase (NSE) in cerebrospinal fl uid and serum: implications in clinical practice. Clin Chem Lab Med 43:1215–1217
63. Planche V, Brochet C, Bakkouch A et al (2010) Importance of hemolysis on neuron-specifi c enolase measurement. Ann Biol Clin 68:239–242
64. Braga F, Ferraro S, Mozzi R et al (2013) Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specifi c enolase. Clin Biochem 46:148–151
65. Dittadi R, Gion M (2013) Re: biological variation of neuroendocrine tumor markers chromogranin A and neuron-specifi c enolase. Clin Biochem 46:1145
66. Prinz RA, Marangos PJ (1982) Use of neuron specifi c enolase as a serum marker for neuroendocrine neoplasms. Surgery 97:887–889
67. Ferolla P, Faggiano A, Mansueto G et al (2008) The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest 31:277–286
68. Pearse AG (1969) The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 17:303–313
69. Jiang SX, Kameya T, Shoji M et al (1998) Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 22:526–537
70. Baudin E, Bidart JM, Rougier P et al (1999) Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab 84:69–75
71. World Health Organization (1982) The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 77:123–136
72. Quoix E, Purohit A, Faller-Beau M et al (2000) Comparative prognostic value of lactate dehydrogenase and neuron-specifi c enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 30:127–134
73. Cooper EH, Splinter TA, Brown DA et al (1985) Evaluation of a radioimmunoassay for neuron specifi c enolase in small cell lung cancer. Br J Cancer 52:333–338
74. Harding M, McAllister J, Hulks G et al (1990) Neurone specifi c enolase (NSE) in small cell lung cancer: a tumour marker of prognostic signifi cance? Br J Cancer 61:605–607
75. Gronowitz JS, Bergström R, Nôu E et al (1990) Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66:722–732
76. Spinazzi A, Soresi E, Borghini U et al (1990) Clinical value of neuron specifi c enolase and tissue polipeptidic antigen for the management of patients with lung cancer. J Nucl Med Allied Sci 34:141–145
77. Giovanella L, Ceriani L, Bandera M et al (1995) Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Int J Biol Markers 10:156–160
78. Giovanella L, Piantanida R, Ceriani L et al (1997) Immunoassay of neuron-specifi c enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Int J Biol Markers 12:22–26
79. Paone G, De Angelis G, Munno R et al (1995) Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Eur Respir J 8:1136–1140
80. Paone G, De Angelis G, Portalone L et al (1997) Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors. Br J Cancer 75:448–450
81. Jørgensen LG, Osterlind K, Genollá J et al (1996) Serum neuron-specifi c enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 74:463–467
82. Esscher T, Steinholtz L, Bergh J et al (1985) Neurone specifi c enolase: a useful diagnostic serum marker for small cell carcinoma of the lung. Thorax 40:85–90
83. Takada M, Kusunoki Y, Masuda N et al (1996) Progastrin- releasing peptide (31–98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specifi c enolase. Br J Cancer 73:1227–1232
84. Giovanella L, Ceriani L, Bandera M et al (2001) Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specifi c enolase. Int J Biol Markers 16:50–55
85. Petrović M, Bukumirić Z, Zdravković V et al (2014) The prognostic signifi cance of the circulating neuroendocrine markers chromogranin A, pro-gastrinreleasing peptide, and neuron-specifi c enolase in patients with small-cell lung cancer. Med Oncol 31:823
86. Broers JL, Carney DN, de Ley L et al (1985) Differential expression of intermediate fi lament proteins distinguishes classic from variant small-cell lung cancer cell lines. Proc Natl Acad Sci U S A 82:4409–4413
87. Kulpa J, Wójcik E, Reinfuss M et al (2002) Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specifi c enolase in squamous cell lung cancer patients. Clin Chem 48:1931–1937
88. Pujol JL, Boher JM, Grenier J et al (2001) Cyfra 21-1, neuron specifi c enolase and prognosis of nonsmall cell lung cancer: prospective study in 621 patients. Lung Cancer 31:221–231
89. Tiseo M, Ardizzoni A, Cafferata MA et al (2008) Predictive and prognostic signifi cance of neuronspecifi c enolase (NSE) in non-small cell lung cancer. Anticancer Res 28:507–513
90. Andoh M, Gemma A, Takenaka K et al (1994) Serum neuron specifi c enolase level as a prognostic factor in non-small cell lung cancer. Intern Med 33:271–276
91. Diez M, Torres A, Ortega L et al (1993) Value of serum neuron-specifi c enolase in nonsmall cell lung cancer. Oncology 50:127–131
92. Yan HJ, Tan Y, Gu W (2014) Neuron specifi c enolase and prognosis of non-small cell lung cancer: a systematic review and meta-analysis. J BUON 19:153–156
93. Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76
94. Cotterill SJ, Pearson AD, Pritchard J et al (2000) Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992. Eur J Cancer 36:901–908
95. Zeltzer PM, Marangos PJ, Parma AM et al (1983) Raised neuron-specifi c enolase in serum of children with metastatic neuroblastoma. A report from the Children’s Cancer Study Group. Lancet 2:361–363
96. Zeltzer PM, Marangos PJ, Evans AE et al (1986) Serum neuron-specifi c enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 57:1230–1234
97. Riley RD, Heney D, Jones DR et al (2004) A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10:4–12
98. Kintzel K, Sonntag J, Strauss E et al (1998) Neuronspecifi c enolase: reference values in cord blood. Clin Chem Lab Med 36:245–247
99. Missler U, Wiesmann M, Friedrich C et al (1997) S-100 protein and neuron-specifi c enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 28:1956–1960
100. Oh SH, Lee JG, Na SJ et al (2003) Prediction of early clinical severity and extent of neuronal damage in anterior-circulation infarction using the initial serum neuron-specifi c enolase level. Arch Neurol 60:37–41
101. Wunderlich MT, Lins H, Skalej M et al (2006) Neuron-specifi c enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 108:558–563
102. Brouns R, De Vil B, Cras P et al (2010) Neurobiochemical markers of brain damage in cerebrospinal fl uid of acute ischemic stroke patients. Clin Chem 56:451–458
103. González-García S, González-Quevedo A, Fernández-Concepción O et al (2012) Short-term prognostic value of serum neuron specifi c enolase and S100B in acute stroke patients. Clin Biochem 45:1302–1307
104. Zaheer S, Beg M, Rizvi I et al (2013) Correlation between serum neuron specifi c enolase and functional neurological outcome in patients of acute ischemic stroke. Ann Indian Acad Neurol 16:504–508
105. Ahmad O, Wardlaw J, Whiteley WN (2012) Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovasc Dis 33:47–54
106. Brea D, Sobrino T, Blanco M et al (2009) Temporal profi le and clinical signifi cance of serum neuronspecifi c enolase and S100 in ischemic and hemorrhagic stroke. Clin Chem Lab Med 47:1513–1518
107. Lee SY, Choi YC, Kim JH et al (2010) Serum neuron- specifi c enolase level as a biomarker in differential diagnosis of seizure and syncope. J Neurol 257:1708–1712
108. Wijdicks EF, Hijdra A, Young GB et al (2006) Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 67:203–210
109. Meynaar IA, Oudemans-van Straaten HM, van der Wetering J et al (2003) Serum neuron-specifi c enolase predicts outcome in post-anoxic coma: a prospective cohort study. Intensive Care Med 29:189–195
110. Guzel A, Er U, Tatli M et al (2008) Serum neuronspecifi c enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury. Neurosurg Rev 31:439–444
111. Meric E, Gunduz A, Turedi S et al (2010) The prognostic value of neuron-specifi c enolase in head trauma patients. J Emerg Med 38:297–301
112. Vos PE, Jacobs B, Andriessen TM et al (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786–1793
113. Wibe E, Hannisdal E, Paus E et al (1992) Neuronspecifi c enolase as a prognostic factor in metastatic malignant melanoma. Eur J Cancer 28:1692–1695
114. Tofani A, Cioffi RP, Sciuto R et al (1997) S-100 and NSE as serum markers in melanoma. Acta Oncol 36:761–764
115. Shine BS, Hungerford J, Vaghela B et al (1990) Electrophoretic assessment of aqueous and serum neurone-specifi c enolase in retinoblastoma and ocular malignant melanoma. Br J Ophthalmol 74:427–430
116. Fosså SD, Klepp O, Paus E (1992) Neuron-specifi c enolase – a serum tumour marker in seminoma? Br J Cancer 65:297–299
117. Tandstad T, Klepp O (2003) Neuron-specifi c enolase in testicular cancer – clinical experiences with serum neuron-specifi c enolase in patients with testicular cancer at diagnosis and during follow-up. Acta Oncol 42:202–206
118. Takashi M, Haimoto H, Tanaka J et al (1989) Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. J Urol 141:830–834
119. Plowman PN (1989) Serum marker for Merkel cell tumour. Clin Radiol 40:542
120. Cunningham RT, Johnston CF, Irvine GB et al (1992) Serum neurone-specifi c enolase levels in patients with neuroendocrine and carcinoid tumours. Clin Chim Acta 212:123–131
121. Kawata M, Sekiya S, Hatakeyama R et al (1989) Neuron-specifi c enolase as a serum marker for immature teratoma and dysgerminoma. Gynecol Oncol 32:191–197
122. Grouzmann E, Gicquel C, Plouin PF et al (1990) Neuropeptide Y and neuron-specifi c enolase levels in benign and malignant pheochromocytomas. Cancer 66:1833–1835
123. O’Connor TP, Wade TP, Sunwoo YC et al (1992) Small cell undifferentiated carcinoma of the pancreas. Report of a patient with tumor marker studies. Cancer 70:1514–1519
124. Mokuno K, Kiyosawa K, Sugimura K et al (1994) Prognostic value of cerebrospinal fl uid neuronspecifi c enolase and S-100b protein in Guillain- Barré syndrome. Acta Neurol Scand 89:27–30
125. Vermuyten K (1989) Determination of glial fi brillary acidic protein, S100, myelin basic protein and neuron specifi c enolase in cerebrospinal fl uid from patients suffering from dementia. Acta Neurol Belg 89:318
126. Aksamit AJ Jr, Preissner CM, Homburger HA (2001) Quantitation of 14-3-3 and neuron-specifi c enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 57:728–730
127. Egan MF, el-Mallakh RS, Suddath RL et al (1992) Cerebrospinal fl uid and serum levels of neuronspecifi c enolase in patients with schizophrenia. Psychiatry Res 43:187–195